Abstract:In previous studies examining the structural determinants of antidepressant and substrate recognition by serotonin transporters (SERTs), we identified Tyr-95 in transmembrane segment 1 (TM1) of human SERT as a major determinant of binding for several antagonists, including racemic citalopram ((RS)-CIT). Here we described a separate site in hSERT TM3 (Ile-172) that impacts (RS)-CIT recognition when switched to the corresponding Drosophila SERT residue (I172M). The hSERT I172M mutant displays a marked loss of inhibitor potency for multiple inhibitors such as (RS)-CIT, clomipramine, RTI-55, fluoxetine, cocaine, nisoxetine, mazindol, and nomifensine, whereas recognition of substrates, including serotonin and 3,4-methylenedioxymethamphetamine, is unaffected. Selectivity for antagonist interactions is evident with this substitution because the potencies of the antidepressants tianeptine and paroxetine are unchanged. Reduced cocaine analog recognition was verified in photoaffinity labeling studies using [(125)I]MFZ 2-24. In contrast to the I172M substitution, other substitutions at this position significantly affected substrate recognition and/or transport activity. Additionally, the mouse mutation (mSERT I172M) exhibits similar selective changes in inhibitor potency. Unlike hSERT or mSERT, analogous substitutions in mouse dopamine transporter (V152M) or human norepinephrine transporter (V148M) result in transporters that bind substrate but are deficient in the subsequent translocation of the substrate. A double mutant hSERT Y95F/I172M had a synergistic impact on (RS)-CIT recognition ( approximately 10,000-fold decrease in (RS)-CIT potency) in the context of normal serotonin recognition. The less active enantiomer (R)-CIT responded to the I172M substitution like (S)-CIT but was relatively insensitive to the Y95F substitution and did not display a synergistic loss at Y95F/I172M. An hSERT mutant with single cysteine substitutions in TM1 and TM3 resulted in formation of a high affinity cadmium metal coordination site, suggesting proximity of these domains in the tertiary structure of SERT. These studies provided evidence for distinct binding sites coordinating SERT antagonists and revealed a close interaction between TM1 and TM3 differentially targeted by stereoisomers of CIT.

Ligand interaction with the purified serotonin transporter in solution and at the air/water interface

Ligand coupling mechanism of the human serotonin transporter differentiates substrates from inhibitors

Determining Ligand and Ion-Induced Conformational Changes in Serotonin Transporter with Its Fluorescent Substrates

The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter

X-ray structures and mechanism of the human serotonin transporter

Computational Approaches for the Study of Serotonin and Its Membrane Transporter SERT: Implications for Drug Design in Neurological Sciences

Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants

The Cytoplasmic Substrate Permeation Pathway of Serotonin Transporter

Serotonin transporter: Recent progress of in silico ligand prediction methods and structural biology towards structure-guided in silico design of therapeutic agents

Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylene dioxymethamphetamine

Cholesterol binding to a conserved site modulates the conformation, pharmacology, and transport kinetics of the human serotonin transporter

Free energy profile of the substrate‐induced occlusion of the human serotonin transporter

Physical and functional interactions between the serotonin transporter and the neutral amino acid transporter ASCT2

Structural insights into the lipid and ligand regulation of serotonin receptors

Serotonin transporter production and degradation rates: studies with RTI-76

Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response

Ligand Selectivity among the Dopamine and Serotonin Transporters Specified by the Forward Binding Reaction

S-Palmitoylation of the serotonin transporter promotes its cell surface expression and serotonin uptake

Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter

Structural Rearrangement of the Serotonin Transporter Intracellular Gate Induced by Thr276 Phosphorylation

Antidepressant‐induced internalization of the serotonin transporter in serotonergic neurons